These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 8002779

  • 21. Differential susceptibility of retroviruses to nucleoside analogues.
    Rosenblum LL, Patton G, Grigg AR, Frater AJ, Cain D, Erlwein O, Hill CL, Clarke JR, McClure MO.
    Antivir Chem Chemother; 2001 Mar; 12(2):91-7. PubMed ID: 11527046
    [Abstract] [Full Text] [Related]

  • 22. Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group.
    Mayers DL, Japour AJ, Arduino JM, Hammer SM, Reichman R, Wagner KF, Chung R, Lane J, Crumpacker CS, McLeod GX.
    Antimicrob Agents Chemother; 1994 Feb; 38(2):307-14. PubMed ID: 8192457
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds.
    Brennan TM, Taylor DL, Bridges CG, Leyda JP, Tyms AS.
    Antiviral Res; 1995 Mar; 26(2):173-87. PubMed ID: 7541619
    [Abstract] [Full Text] [Related]

  • 27. Studies of zidovudine in combination with didanosine and zalcitabine.
    Jablonowski H.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Mar; 10 Suppl 1():S52-6. PubMed ID: 8595509
    [Abstract] [Full Text] [Related]

  • 28. Antiretroviral drug resistance.
    Japour AJ.
    AIDS Clin Care; 1995 Aug; 7(8):63-5, 67. PubMed ID: 11362787
    [Abstract] [Full Text] [Related]

  • 29. Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs.
    Mayers DL.
    Am J Med; 1997 May 19; 102(5B):70-5. PubMed ID: 9845501
    [Abstract] [Full Text] [Related]

  • 30. Didanosine and zidovudine resistance patterns in clinical isolates of human immunodeficiency virus type 1 as determined by a replication endpoint concentration assay.
    McLeod GX, McGrath JM, Ladd EA, Hammer SM.
    Antimicrob Agents Chemother; 1992 May 19; 36(5):920-5. PubMed ID: 1510414
    [Abstract] [Full Text] [Related]

  • 31. Suppression of replication of multidrug-resistant HIV type 1 variants by combinations of thymidylate synthase inhibitors with zidovudine or stavudine.
    Gao WY, Johns DG, Tanaka M, Mitsuya H.
    Mol Pharmacol; 1999 Mar 19; 55(3):535-40. PubMed ID: 10051538
    [Abstract] [Full Text] [Related]

  • 32. Synergistic inhibition of HIV-1 in activated and resting peripheral blood mononuclear cells, monocyte-derived macrophages, and selected drug-resistant isolates with nucleoside analogues combined with a natural product, resveratrol.
    Heredia A, Davis C, Redfield R.
    J Acquir Immune Defic Syndr; 2000 Nov 01; 25(3):246-55. PubMed ID: 11115955
    [Abstract] [Full Text] [Related]

  • 33. Biological comparison of wild-type and zidovudine-resistant isolates of human immunodeficiency virus type 1 from the same subjects: susceptibility and resistance to other drugs.
    Rooke R, Parniak MA, Tremblay M, Soudeyns H, Li XG, Gao Q, Yao XJ, Wainberg MA.
    Antimicrob Agents Chemother; 1991 May 01; 35(5):988-91. PubMed ID: 1649576
    [Abstract] [Full Text] [Related]

  • 34. An HIV-1 215V mutant shows increased phenotypic resistance to d4T.
    Pernas M, López-Galíndez C.
    Virus Res; 2008 Aug 01; 135(2):340-4. PubMed ID: 18482778
    [Abstract] [Full Text] [Related]

  • 35. Ganciclovir antagonizes the anti-human immunodeficiency virus type 1 activity of zidovudine and didanosine in vitro.
    Medina DJ, Hsiung GD, Mellors JW.
    Antimicrob Agents Chemother; 1992 May 01; 36(5):1127-30. PubMed ID: 1510405
    [Abstract] [Full Text] [Related]

  • 36. Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells.
    Benbrik E, Chariot P, Bonavaud S, Ammi-Saïd M, Frisdal E, Rey C, Gherardi R, Barlovatz-Meimon G.
    J Neurol Sci; 1997 Jul 01; 149(1):19-25. PubMed ID: 9168161
    [Abstract] [Full Text] [Related]

  • 37. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro.
    Larder BA, Kellam P, Kemp SD.
    Nature; 1993 Sep 30; 365(6445):451-3. PubMed ID: 7692302
    [Abstract] [Full Text] [Related]

  • 38. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
    Chow YK, Hirsch MS, Merrill DP, Bechtel LJ, Eron JJ, Kaplan JC, D'Aquila RT.
    Nature; 1993 Feb 18; 361(6413):650-4. PubMed ID: 7679778
    [Abstract] [Full Text] [Related]

  • 39. In vitro susceptibility of clinical isolates of HIV-1 to XM323, a non-peptidyl HIV protease inhibitor.
    Winslow DL, Mayers D, Scarnati H, Lane J, Bincsik A, Otto MJ.
    AIDS; 1994 Jun 18; 8(6):753-6. PubMed ID: 8086132
    [Abstract] [Full Text] [Related]

  • 40. Pharmacodynamic studies (PD) of didanosine (ddI) alone and in combination with azidothymidine (AZT) in human T-cells; a stochastic biochemical approach to antiretroviral nucleoside drug combination in inhibiting HIV-reverse transcriptase (RT).
    Periclou AP, Nandy P, Avramis VI.
    In Vivo; 2000 Jun 18; 14(3):377-88. PubMed ID: 10904870
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.